Macrophages promote progression of lung cancer by regulating ubiquitin-specific peptidase 17 in cancer cells

Chih-Hao Lu, Chao-Yang Lai and Tsung-Hsien Chuang*
Immunology Research Center, National Health Research Institutes, Taiwan

Tumor-associated macrophages (TAMs) are stromal cells in the tumor microenvironment that affect the progression of tumor development. Macrophages can be divided into different subsets based on their functions. A simplistic model is that M1 (or classically activated) macrophages favor the immunosurveillance of malignant cells and M2 (or alternatively activated) macrophages exert immunosuppressive effects and perform protumoral functions. TAMs are not a single uniform population. They exhibit features that are intermediate between the M1 and M2 macrophage phenotypes. In some cancer types such as lung cancer, extensive accumulation of TAMs is often associated with poor prognosis. In addition to the regulation of immunological responses, TAMs promote tumor progression through the regulation of cancer cell proliferation, invasion, and metastasis. Therefore, the molecular mechanisms underlying the interaction between macrophages and cancer cells to build a protumoral microenvironment were investigated with the goal of developing antitumor strategies [1-4].

Ubiquitination is a post-translational modification process that is involved in several cellular functions. Specific ubiquitination of a target protein is mediated by E3 ubiquitin–protein ligase and is counteracted by deubiquitinases. Dysfunction of this ubiquitination–deubiquitination process has been linked to human diseases, including cancers [5-7]. Ubiquitin-specific protease 17 (USP17, also termed as DUB3) is a cytokine-inducible deubiquitinase [8]. A recent study demonstrated a high expression of USP17 in lung cancers. The expression of this deubiquitinase was found to increase in parallel with the increase in cancer stages, suggesting that USP17 expression is associated with poor prognosis in lung cancers [9]. Consistent with these findings, the analysis of the Oncomine database revealed that high levels of USP17 expression were also observed in cervical, gastric, and breast cancers (Figure 1). Moreover, results from the cBioPortal database analysis demonstrated a correlation between high USP17 expression and a low survival rate in patients with thyroid carcinoma (Figure 2).

Different molecular mechanisms underlying the protumoral function of USP17 have been reported. Earlier studies have suggested that this deubiquitinase promotes oncogenic transformation through the regulation of cell cycle progression. USP17 expression is required for G1-S progression through the regulation of the cyclin-dependent kinase inhibitors p21 and p27 [10]. The deubiquitinase activity of USP17 protects Cdc25A from proteasomal degradation and promotes the cell-transforming ability [11]. More recent studies have demonstrated that USP17 is involved in the regulation of the epithelial–mesenchymal transition (EMT) phenotype and cancer invasion by stabilizing snail1, slug, twist, and SMAD4 through its deubiquitination activity [12-15]. Another study reported that USP17 deubiquitinates a bromodomain and an extraterminal domain (BET) protein, BRD4, to promote tumor progression [16].

The tumor microenvironment contains abundant cytokines, and TAMs are a major source of these cytokines. Therefore, the expression and function of USP17 in cancer cells in mediating the protumoral effect of macrophages were investigated [9]. The expression of USP17 was elevated in correlation with the expression of inflammatory markers and macrophage markers in lung cancers. Both the M1 type and the M2 type of macrophages promoted the expression of USP17 in lung cancer cells, and this effect was caused due to the cytokines produced

Data of USP17 expression levels in the normal and cancer tissues as indicated were acquired from data sets in the Oncomine database for analysis. Red: accession number for the data set. Tissue sample numbers are shown in parentheses.

*Correspondence to: Tsung-Hsien Chuang, Immunology Research Center, National Health Research Institutes, 35, Keyan Road, Zhunan, Miaoli County 35053, Taiwan, E-mail: thchuang@nhri.org.tw

Key words: macrophage, inflammation, stemness, ubiquitin-specific peptidase 17

Received: September 28, 2018; Accepted: October 12, 2018; Published: October 16, 2018
by these macrophages. An increased expression of USP17 enhances inflammation and stemness in cancer cells by stabilizing key signaling molecules and transcription factors, including NF-κB-inducing kinase (NIK), c-Rel, and interferon regulatory factor 5 (IRF5). Proteolytic degradation of these proteins is promoted by a TNF-receptor-associated factor 2 (TRAF2)/TRAF3 complex. USP17 contains TRAF2- and TRAF3-binding domains, which allow it to interact and disrupt the protein degradation capability of this TRAF2/TRAF3 complex. In addition, the expression of USP17 in cancer cells promotes macrophage recruitment and cytokine production by macrophages. Animal studies have demonstrated that there was a reduction in the tumor growth rate, USP17 expression, and inflammatory cytokine production in tumors grown in macrophage-depleted mice compared with that in control mice. Moreover, there was a faster tumor growth rate, increased leukocyte infiltration, and inflammation- and stemness-associated gene expressions in tumors derived from USP17-overexpressed lung cancer cells compared with those derived from control cancer cells [9]. These results suggested a positive role of USP17 expression in lung cancer cells in the protumoral function of macrophages.

References

8. Lim KH, Ramakrishna S, Baek KH (2013) Molecular mechanisms and functions of cytokine-inducible deubiquitinating enzymes. Cytokine Growth Factor Rev 24:427-431. [Crossref]
15. Song C, Liu W, Li J (2017) USP17 is upregulated in osteosarcoma and promotes cell proliferation, metastasis, and epithelial-mesenchymal transition through stabilizing SMAD4. Tumour Biol. [Crossref]